HARPOON THERAPEUTICS INC (HARP) Stock Analyst Ratings
USA - NASDAQ:HARP - US41358P2056 - Common Stock
23.01 USD
+0.02 (+0.09%)
23 USD
-0.01 (-0.04%)
ChartMill assigns a Buy % Consensus number of 72% to HARP. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.14. This target is 4.93% above the current price.
HARP was analyzed by 15 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about HARP.
In the previous month the buy percentage consensus was at a similar level.
HARP was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-02-26 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-01-16 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2024-01-08 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-01-05 | Oppenheimer | Initiate | Outperform |
| 2023-12-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-20 | TD Cowen | Initiate | Outperform |
| 2023-10-24 | Citigroup | Maintains | Buy -> Buy |
| 2023-09-18 | Citigroup | Maintains | Buy -> Buy |
| 2023-09-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023-09-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-03 | Canaccord Genuity | Maintains | Buy |
| 2023-03-29 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-14 | Truist Securities | Downgrade | Buy -> Hold |
| 2022-11-15 | SVB Leerink | Maintains | Outperform |
| 2022-11-15 | Baird | Downgrade | Outperform -> Neutral |
| 2022-08-29 | Citigroup | Maintains | Buy |
| 2022-08-23 | Truist Securities | Maintains | Buy |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-11 | SVB Leerink | Maintains | Outperform |
| 2022-08-11 | Piper Sandler | Maintains | Overweight |
| 2022-05-16 | Wedbush | Upgrade | Neutral -> Outperform |
| 2021-11-11 | SVB Leerink | Maintains | Outperform |
| 2021-09-28 | Citigroup | Upgrade | Neutral -> Buy |
| 2021-08-06 | SVB Leerink | Maintains | Outperform |
| 2021-06-08 | Citigroup | Downgrade | Buy -> Neutral |
| 2021-06-07 | Wedbush | Downgrade | Outperform -> Neutral |
| 2021-05-28 | Cantor Fitzgerald | Initiate | Overweight |
HARPOON THERAPEUTICS INC / HARP FAQ
What is the price target for HARP stock?
15 analysts have analysed HARP and the average price target is 24.14 USD. This implies a price increase of 4.93% is expected in the next year compared to the current price of 23.01.
How do analysts rate HARPOON THERAPEUTICS INC (HARP)?
The consensus rating for HARPOON THERAPEUTICS INC (HARP) is 72 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed HARPOON THERAPEUTICS INC (HARP)?
The number of analysts covering HARPOON THERAPEUTICS INC (HARP) is 15.